SEC Tracker
Get the app
Person · CIK 1678419

Atabak Mokari

Chief Financial Officer at Corcept Therapeutics

Earlier: Bellicum Pharmaceuticals and Iridex

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$18.7M
Noticed on Form 144$15.8M
Bought on Form 4$0
Companies3

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

CompanySecurityHeldShares or unitsAs of
Corcept Therapeutics CORTCommon StockDirectly16,304Sep 2, 2026 · Filing · EDGAR
Corcept Therapeutics CORTStock option (right to buy)
exercise $23.06, expires Feb 13, 2033, into Common Stock
Directly95,833Jul 30, 2026 · Filing · EDGAR
Bellicum PharmaceuticalsRestricted Stock Units
into Common Stock
Directly21,792Apr 8, 2020 · Filing · EDGAR
IridexCommon StockDirectly81,787Dec 11, 2018 · Filing · EDGAR

Sold and noticed by quarter

Atabak Mokari: dollars sold on Form 4 and noticed on Form 144 per quarter, Q1 2025 to Q4 2026$12.7M$0Q1 2025: $0 noticed on Form 144Q1 2025: $0 sold on Form 4Q2 2025: $0 noticed on Form 144Q2 2025: $0 sold on Form 4Q3 2025: $0 noticed on Form 144Q3 2025: $0 sold on Form 4Q4 2025: $0 noticed on Form 144Q4 2025: $0 sold on Form 4Q1 2026: $0 noticed on Form 144Q1 2026: $0 sold on Form 4Q2 2026: $11.2M noticed on Form 144Q2 2026: $6M sold on Form 4Q3 2026: $4.6M noticed on Form 144Q3 2026: $12.7M sold on Form 4Q4 2026: $0 noticed on Form 144Q4 2026: $0 sold on Form 4Q1 2025Q3 2025Q1 2026Q3 2026

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table
QuarterSold (Form 4)Noticed (Form 144)
Q3 2026$12.7M$4.6M
Q2 2026$6M$11.2M

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice dateNoticedPlanned saleOutcomeLinks
Corcept Therapeutics CORT · Stifel Nicolaus & Company · 10b5-1 plan adopted Dec 12, 2025 · 2 notices
Jul 30, 202640,000 · ~$4.6MJul 30, 2026Partly sold Sold 38,682 in 5 sales, Jul 30 to Jul 30 · $4.5M likely match Form 4Filing · EDGAR
Jun 1, 2026160,000 · ~$11.2MJun 1, 2026Sold as noticed Sold 161,318 in 17 sales, Jun 1 to Jul 30 · $14.2M Form 4 (1) · Form 4 (2) · Form 4 (3) · Form 4 (4)Filing · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

Corcept Therapeutics CORT Chief Financial Officer · filings 2021 to 2026 · sold $18.7M · $15.8M noticed on Form 144

DateTransactionSharesPriceValueHeld afterSource
Sep 2, 2026Shares withheld for tax or exercise price−102$113.38$12K16,304 directFiling · EDGAR
Sep 1, 2026Grant or award from the company+138$113.38$16K16,268 directFiling · EDGAR
Sep 1, 2026Grant or award from the company+13816,406 directFiling · EDGAR
Jul 30, 2026Option or RSU exercised or converted+80,000$23.06$1.8M96,130 directFiling · EDGAR
Jul 30, 2026Sale under a 10b5-1 plan−4,200$105.54$443K91,930 directFiling · EDGAR
Jul 30, 2026Sale under a 10b5-1 plan−8,956$106.96$958K82,974 directFiling · EDGAR
Jul 30, 2026Sale under a 10b5-1 plan−400$108.46$43K82,574 directFiling · EDGAR
Jul 30, 2026Sale under a 10b5-1 plan−2,202$110.03$242K80,372 directFiling · EDGAR
Jul 30, 2026Sale under a 10b5-1 plan−600$110.95$67K79,772 directFiling · EDGAR
Jul 30, 2026Sale under a 10b5-1 plan−4,700$113.18$532K75,072 directFiling · EDGAR
Jul 30, 2026Sale under a 10b5-1 plan−15,477$114.96$1.8M59,595 directFiling · EDGAR
Jul 30, 2026Sale under a 10b5-1 plan−14,222$115.87$1.6M45,373 directFiling · EDGAR
Jul 30, 2026Sale under a 10b5-1 plan−7,089$116.96$829K38,284 directFiling · EDGAR
Jul 30, 2026Sale under a 10b5-1 plan−8,267$117.93$975K30,017 directFiling · EDGAR
Jul 30, 2026Sale under a 10b5-1 plan−4,783$118.73$568K25,234 directFiling · EDGAR
Jul 30, 2026Sale under a 10b5-1 plan−8,103$119.95$972K17,131 directFiling · EDGAR
Jul 30, 2026Sale under a 10b5-1 plan−1,001$120.67$121K16,130 directFiling · EDGAR
Jul 30, 2026Option or RSU exercised or converted
Stock option (right to buy)
−80,00095,833 directFiling · EDGAR
Jul 15, 2026Option or RSU exercised or converted+15,833$19.26$305K31,963 directFiling · EDGAR
Jul 15, 2026Option or RSU exercised or converted+24,167$23.06$557K56,130 directFiling · EDGAR
Jul 15, 2026Sale under a 10b5-1 plan−7,919$86.78$687K48,211 directFiling · EDGAR
Jul 15, 2026Sale under a 10b5-1 plan−28,460$87.89$2.5M19,751 directFiling · EDGAR
Jul 15, 2026Sale under a 10b5-1 plan−3,520$88.30$311K16,231 directFiling · EDGAR
Jul 15, 2026Sale under a 10b5-1 plan−101$89.43$9K16,130 directFiling · EDGAR
Jul 15, 2026Option or RSU exercised or converted
Stock option (right to buy)
−15,8334,167 directFiling · EDGAR
Jul 15, 2026Option or RSU exercised or converted
Stock option (right to buy)
−24,167175,833 directFiling · EDGAR
Jun 15, 2026Option or RSU exercised or converted+40,000$19.26$770K56,130 directFiling · EDGAR
Jun 15, 2026Sale under a 10b5-1 plan−9,434$80.02$755K46,696 directFiling · EDGAR
Jun 15, 2026Sale under a 10b5-1 plan−11,081$80.94$897K35,615 directFiling · EDGAR
Jun 15, 2026Sale under a 10b5-1 plan−19,483$81.81$1.6M16,132 directFiling · EDGAR
Jun 15, 2026Sale under a 10b5-1 plan−2$82.45$16516,130 directFiling · EDGAR
Jun 15, 2026Option or RSU exercised or converted
Stock option (right to buy)
−40,00020,000 directFiling · EDGAR
Jun 2, 2026Shares withheld for tax or exercise price−395$70.44$28K16,130 directFiling · EDGAR
Jun 1, 2026Option or RSU exercised or converted+40,000$19.26$770K55,257 directFiling · EDGAR
Jun 1, 2026Sale under a 10b5-1 plan−40,000$70.00$2.8M15,257 directFiling · EDGAR
Jun 1, 2026Grant or award from the company+634$70.44$45K15,891 directFiling · EDGAR
Jun 1, 2026Grant or award from the company+63416,525 directFiling · EDGAR
Jun 1, 2026Option or RSU exercised or converted
Stock option (right to buy)
−40,00060,000 directFiling · EDGAR
Mar 3, 2026Shares withheld for tax or exercise price−96$35.97$3K15,257 directFiling · EDGAR
Mar 2, 2026Grant or award from the company+397$35.97$14K14,956 directFiling · EDGAR
Mar 2, 2026Grant or award from the company+39715,353 directFiling · EDGAR
Feb 27, 2026Grant or award from the company
Stock Option (right to buy)
+140,000140,000 directFiling · EDGAR
Dec 2, 2025Shares withheld for tax or exercise price−118$79.78$9K14,559 directFiling · EDGAR
Dec 1, 2025Grant or award from the company+178$79.78$14K14,499 directFiling · EDGAR
Dec 1, 2025Grant or award from the company+17814,677 directFiling · EDGAR
Sep 3, 2025Shares withheld for tax or exercise price−144$71.38$10K14,321 directFiling · EDGAR
Sep 2, 2025Grant or award from the company+200$71.38$14K14,265 directFiling · EDGAR
Sep 2, 2025Grant or award from the company+20014,465 directFiling · EDGAR
Jun 3, 2025Shares withheld for tax or exercise price−519$71.68$37K14,065 directFiling · EDGAR
Jun 2, 2025Grant or award from the company+775$71.68$56K13,809 directFiling · EDGAR
Jun 2, 2025Grant or award from the company+77514,584 directFiling · EDGAR
Mar 3, 2025Shares withheld for tax or exercise price−228$60.58$14K12,570 directFiling · EDGAR
Mar 3, 2025Grant or award from the company+232$59.07$14K12,802 directFiling · EDGAR
Mar 3, 2025Grant or award from the company+23213,034 directFiling · EDGAR
Feb 28, 2025Grant or award from the company
Stock option (right to buy)
+140,000140,000 directFiling · EDGAR
Dec 2, 2024Shares withheld for tax or exercise price−182$57.68$10K12,336 directFiling · EDGAR
Dec 2, 2024Grant or award from the company+231$59.21$14K12,567 directFiling · EDGAR
Dec 2, 2024Grant or award from the company+23112,798 directFiling · EDGAR
Sep 3, 2024Shares withheld for tax or exercise price−143$35.30$5K11,718 directFiling · EDGAR
Sep 3, 2024Grant or award from the company+400$34.26$14K12,118 directFiling · EDGAR

21 earlier transactions are in the filing list below.

Bellicum Pharmaceuticals Chief Financial Officer · filings 2018 to 2020

DateTransactionSharesPriceValueHeld afterSource
Apr 8, 2020Grant or award from the company
Restricted Stock Units
+21,79221,792 directFiling · EDGAR
Feb 3, 2020Grant or award from the company
Stock Option (right to buy)
+540,000540,000 directFiling · EDGAR
Dec 19, 2018Grant or award from the company
Stock Option (right to buy)
+300,000300,000 directFiling · EDGAR

Iridex CFO and VP Corp Development · filings 2016 to 2018

DateTransactionSharesPriceValueHeld afterSource
Dec 11, 2018Shares withheld for tax or exercise price−180$4.10$73881,787 directFiling · EDGAR
Nov 24, 2018Shares withheld for tax or exercise price−5,83381,967 directFiling · EDGAR
Jul 28, 2018Grant or award from the company+16,80087,800 directFiling · EDGAR
Jul 24, 2017Grant or award from the company+6,000$9.54$57K71,000 directFiling · EDGAR
Jul 24, 2017Option or RSU exercised or converted
Stock Option Right to Buy
+63,00063,000 directFiling · EDGAR
Jul 27, 2016Grant or award from the company+25,00025,000 directFiling · EDGAR
Jul 27, 2016Grant or award from the company+40,00065,000 directFiling · EDGAR
All 36 Forms 3, 4, 5 and 144
FiledFormCompanyLinks
Sep 3, 2026Form 4Corcept Therapeutics CORTFiling · EDGAR
Aug 3, 2026Form 4Corcept Therapeutics CORTFiling · EDGAR
Jul 30, 2026Form 144Corcept Therapeutics CORTFiling · EDGAR
Jul 17, 2026Form 4Corcept Therapeutics CORTFiling · EDGAR
Jun 17, 2026Form 4Corcept Therapeutics CORTFiling · EDGAR
Jun 3, 2026Form 4Corcept Therapeutics CORTFiling · EDGAR
Jun 1, 2026Form 144Corcept Therapeutics CORTFiling · EDGAR
Mar 4, 2026Form 4Corcept Therapeutics CORTFiling · EDGAR
Mar 3, 2026Form 4Corcept Therapeutics CORTFiling · EDGAR
Dec 3, 2025Form 4Corcept Therapeutics CORTFiling · EDGAR
Sep 4, 2025Form 4Corcept Therapeutics CORTFiling · EDGAR
Jun 4, 2025Form 4Corcept Therapeutics CORTFiling · EDGAR
Mar 4, 2025Form 4Corcept Therapeutics CORTFiling · EDGAR
Dec 4, 2024Form 4Corcept Therapeutics CORTFiling · EDGAR
Sep 5, 2024Form 4Corcept Therapeutics CORTFiling · EDGAR
Jun 5, 2024Form 4Corcept Therapeutics CORTFiling · EDGAR
Mar 5, 2024Form 4Corcept Therapeutics CORTFiling · EDGAR
Feb 13, 2024Form 4Corcept Therapeutics CORTFiling · EDGAR
Dec 5, 2023Form 4Corcept Therapeutics CORTFiling · EDGAR
Sep 6, 2023Form 4Corcept Therapeutics CORTFiling · EDGAR
Jun 5, 2023Form 4Corcept Therapeutics CORTFiling · EDGAR
Mar 3, 2023Form 4Corcept Therapeutics CORTFiling · EDGAR
Feb 15, 2023Form 4Corcept Therapeutics CORTFiling · EDGAR
Sep 6, 2022Form 4Corcept Therapeutics CORTFiling · EDGAR
Feb 11, 2022Form 4Corcept Therapeutics CORTFiling · EDGAR
Mar 3, 2021Form 4Corcept Therapeutics CORTFiling · EDGAR
Mar 3, 2021Form 3Corcept Therapeutics CORTFiling · EDGAR
Apr 9, 2020Form 4Bellicum PharmaceuticalsFiling · EDGAR
Feb 4, 2020Form 4Bellicum PharmaceuticalsFiling · EDGAR
Dec 20, 2018Form 4Bellicum PharmaceuticalsFiling · EDGAR
Dec 20, 2018Form 3Bellicum PharmaceuticalsFiling · EDGAR
Dec 13, 2018Form 4IridexFiling · EDGAR
Jul 31, 2018Form 4IridexFiling · EDGAR
Jul 26, 2017Form 4IridexFiling · EDGAR
Jul 29, 2016Form 4IridexFiling · EDGAR
Jul 13, 2016Form 3IridexFiling · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched . The filing on SEC.gov is the record.